Acebutolol-Induced Subacute Cutaneous Lupus Erythematosus
| Autor: | F. Ben Ammar, Rym Benmously, Hayet Marrak, S. Fenniche, Asma Dhaoui, I. Mokhtar |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Anti-nuclear antibody Physiology Adrenergic beta-Antagonists Physical examination Dermatology Acebutolol Serology Subacute cutaneous lupus erythematosus Lupus Erythematosus Cutaneous Humans Medicine skin and connective tissue diseases Pharmacology Lupus erythematosus Systemic lupus erythematosus medicine.diagnostic_test business.industry General Medicine Middle Aged medicine.disease Antibodies Antinuclear Hypertension Immunology Female business Anti-SSA/Ro autoantibodies medicine.drug |
| Zdroj: | Skin Pharmacology and Physiology. 18:230-233 |
| ISSN: | 1660-5535 1660-5527 |
| DOI: | 10.1159/000086668 |
| Popis: | Beta-blocking medications are rarely associated with drug-induced lupus erythematosus syndrome and have never been incriminated as a cause of subacute lupus erythematosus (SCLE). We present herein the first case of SCLE induced by acebutolol. A 57-year-old woman presented with a 1-month history of a cutaneous eruption of the photoexposed areas. One month ago, the patient had started a treatment with oral acebutolol to cure a hypertension of 1-year evolution. Physical examination revealed erythematous scaly annular plaques, involving the face, arms and trunk. Immunologic serology findings revealed a positive titer of antinuclear antibodies up to 1/1,280 with positivity of antihistone and Ro/SSA antibodies. Acebutolol was stopped, and the lesions cleared completely 4 months later. Literature data, along with our case, suggest a link between acebutolol therapy and the onset of a lupus syndrome. Although this is the first report of acebutolol-induced SCLE, we should be aware of this occurrence, and avoidance of acebutolol is recommended in patients with stigmata of lupus erythematosus |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|